Trial Profile
Phase II, open label, non-randomized, efficacy and safety study of an intravenous formulation of the anthracycline analog, GPX-100, in the treatment of metastatic breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs GPX 100 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Gem Pharmaceuticals
- 05 Oct 2006 New trial record.